To the full analysis
United Therapeutics stock: growth
UTHRUnited Therapeutics reported $3.18B in revenue for fiscal 2025, up 10.6% on the prior year, up 16.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
17.1%
per year from 2006 to 2025, per share 17.3%
Earnings (Annual rate)
16.4%
per year from 2006 to 2025, per share 16.7%
Free cash flow (Annual rate)
19.3%
per year from 2006 to 2025, per share 19.6%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 16.5% | 8.1% | 17.1% |
| Revenue per share | 16.4% | 8.5% | 17.3% |
| Earnings | 21.0% | 7.4% | 16.4% |
| Earnings per share | 20.9% | 7.8% | 16.7% |
| Free cash flow | 8.4% | 12.1% | 19.3% |
| Free cash flow per share | 8.3% | 12.5% | 19.6% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $159.63M | $73.97M | $36.15M |
| 2007 | $210.94M | $19.86M | $10.43M |
| 2008 | $281.5M | −$42.79M | −$173.59M |
| 2009 | $369.85M | $19.46M | $2.22M |
| 2010 | $603.83M | $105.92M | $192.89M |
| 2011 | $743.18M | $217.87M | $214.22M |
| 2012 | $916.08M | $304.44M | $211.72M |
| 2013 | $1.12B | $174.56M | $393.36M |
| 2014 | $1.29B | $340.07M | $307.86M |
| 2015 | $1.47B | $651.64M | $333.01M |
| 2016 | $1.6B | $713.7M | $600.4M |
| 2017 | $1.73B | $417.9M | $387.9M |
| 2018 | $1.63B | $589.2M | $594M |
| 2019 | $1.45B | −$104.5M | −$290.3M |
| 2020 | $1.48B | $514.8M | $696.4M |
| 2021 | $1.69B | $475.8M | $477.4M |
| 2022 | $1.94B | $727.3M | $663.7M |
| 2023 | $2.33B | $984.8M | $747.6M |
| 2024 | $2.88B | $1.2B | $1.08B |
| 2025 | $3.18B | $1.33B | $1.04B |
Revenue by segment
How United Therapeutics Corporation makes its money and how that has shifted. Names are as the company reports them.
- Tyvaso59%
- Remodulin17%
- Orenitram16%
- Unituxin7%
- Other2%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Tyvaso | $607.5M | $873M | $1.23B | $1.62B | $1.88B | 59% |
| Remodulin | $513.7M | $500.2M | $494.8M | $538.1M | $526.8M | 16.6% |
| Orenitram | $306.1M | $325.1M | $359.4M | $434.3M | $496.9M | 15.6% |
| Unituxin | $202.3M | $182.9M | $198.9M | $238.7M | $226.8M | 7.1% |
| Other | $55.9M | $55.1M | $40.7M | $45.9M | $54M | 1.7% |
| Total revenue | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B | 100% |
Revenue by region
Where United Therapeutics Corporation generates its revenue.
- United States95%
- Outside the US5%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| United States | $1.41B | $1.56B | $1.81B | $2.2B | $2.74B | $3.04B | 95.4% |
| Outside the US | no data | $121.3M | $122.2M | $125.3M | $137.7M | $145.7M | 4.6% |
| Other | $71.2M | $0 | $0 | $0 | $0 | $0 | 0% |
| Total revenue | $1.48B | $1.69B | $1.94B | $2.33B | $2.88B | $3.18B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 May 2022)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.